Brief: Shenzhen Hepalink Pharmaceutical Says Enoxaparin Sodium Injection Obtains Approval From Health Canada
09/12/2020 15:06
Dec 9 (Reuters) - Shenzhen Hepalink Pharmaceutical Group Co
Ltd 002399.SZ :
* ANNOUNCES GROUP'S ENOXAPARIN SODIUM INJECTION OBTAINS
APPROVAL
FROM HEALTH CANADA
Source text for Eikon: ID:nHKSbMX4QH
Further company coverage: 002399.SZ
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA